Biodesix, Inc. BDSX Direct Costs And Expenses
Direct Costs And Expenses at other companies
Other financials
Where this comes from
Reported directly by Biodesix, Inc. in its filing.
Tagged under the XBRL concept bdsx:DirectCostsAndExpenses.
The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biodesix, Inc.'s direct costs and expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biodesix, Inc.'s direct costs and expenses?
- Biodesix, Inc. (BDSX) reported direct costs and expenses of $4.21M in Q1 2026.
- How has Biodesix, Inc.'s direct costs and expenses changed year-over-year?
- Biodesix, Inc.'s direct costs and expenses increased by 13.6% year-over-year, from $3.7M to $4.21M.
- What is the long-term trend for Biodesix, Inc.'s direct costs and expenses?
- Over 4 years (2021 to 2025), Biodesix, Inc.'s direct costs and expenses has grown at a -14.0% compound annual growth rate (CAGR), from $30.52M to $16.72M.
- What does direct costs and expenses mean?
- This represents the direct costs and expenses incurred to generate revenue from diagnostic testing services and biopharmaceutical partnerships. It captures the variable costs associated with laboratory operations, testing supplies, and direct service delivery. Monitoring this metric helps assess the direct cost structure and gross margin efficiency of the company's core diagnostic service offerings.